AUS
NZ
UK
CA
USA
IND
Syntara Limited (ASX:SNT), an Australian pharmaceutical firm based in Frenchs Forest, NSW, has announced that its board has approved the issuance of 3,087,108 zero exercise price Options (ZEPOs) to its Chief Executive Officer as a substitute for part of his contracted annual cash salary. This grant, equivalent to $62,359.58 in forgone cash remuneration for FY27, requires Shareholder approval at the company’s 2026 Annual General Meeting. This move aligns with a rising trend among smaller ASX-listed companies to conserve cash by offering Equity-based pay alternatives to senior management. Investors will monitor the AGM vote outcome and the implications this incentive structure has on the company’s executive alignment and Capital management strategy.
Key Points
- Company: Syntara Limited (ASX:SNT)
- Board resolved to grant 3,087,108 ZEPOs to the CEO in lieu of $62,359.58 cash salary for FY27
- ZEPOs are unlisted securities over Syntara ordinary shares with zero issue and exercise prices
- All ZEPOs vest on 30 June 2027, contingent on CEO’s continued employment
- Shares obtained upon exercise are restricted from trading until 30 June 2031 and require Board approval thereafter
- Shareholder approval will be sought at the 2026 Annual General Meeting; issuance follows approval
- Investors should track the AGM date, meeting notice, and shareholder vote results
Syntara CEO Chooses ZEPOs Over $62,359 Cash Portion of FY27 Salary
On 2 July 2026, Syntara Limited revealed that its CEO, Mr Phillips, has opted to receive $62,359.58 of his FY27 contracted cash salary as zero exercise price options (ZEPOs) instead of cash. This arrangement falls under Syntara’s existing employee incentive scheme and complies with the company’s Employee Option Plan. The board’s formal resolution to proceed triggered disclosure obligations under ASX Listing Rule 3.10.3.
This practice, where a senior executive voluntarily exchanges cash pay for equity instruments, is common among smaller listed firms managing cash prudently. For investors, it indicates the CEO’s willingness to link part of his remuneration to the company’s share price performance over time. The company did not disclose the CEO’s total remuneration package or current cash position in this update.
Calculation of 3,087,108 ZEPOs Based on Five-Day VWAP Ending 30 June 2026
The 3,087,108 ZEPOs were determined using a five-day Volume Weighted Average Price (VWAP) of Syntara shares up to and including 30 June 2026. This standard method converts a dollar remuneration amount into an equivalent number of equity instruments based on verifiable market prices rather than arbitrary values.
Using a five-day VWAP reduces distortion from single-day price fluctuations. Although the exact VWAP figure was not disclosed, dividing $62,359.58 by 3,087,108 ZEPOs implies an approximate option price of $0.0202. These ZEPOs will be unlisted and carry zero issue and exercise prices.
Implications of Zero Exercise Price Options for Syntara Shareholders
ZEPOs grant the holder the right to acquire ordinary shares at no cost upon vesting, provided conditions are met. Unlike traditional options requiring an exercise price, ZEPOs convert directly into shares without additional payment. Thus, each ZEPO’s value at exercise equals one ordinary share’s market price on the vesting date.
For current shareholders, the ZEPO issuance could dilute shareholding by up to 3,087,108 shares if exercised. However, since this replaces $62,359.58 in cash salary, the company conserves cash at the expense of potential dilution. Whether this trade-off benefits shareholders depends on views regarding Syntara’s cash needs and future share price.
Vesting Requires CEO Employment Through 30 June 2027
The ZEPOs vest 100% on 30 June 2027, contingent solely on Mr Phillips remaining employed by Syntara at that time. No additional performance criteria were disclosed. This time-based vesting acts as a retention incentive, encouraging the CEO to stay with the company for about one year from the announcement. Unvested ZEPOs would lapse if he departs earlier, though specific lapse terms were not detailed.
Four-Year Trading Restriction on Shares Acquired via ZEPOs Until 30 June 2031
A significant feature is the extended lock-up on shares obtained upon ZEPO exercise. Shares vested on 30 June 2027 cannot be traded until 30 June 2031, and even then only with prior Board approval. This four-year restriction exceeds typical escrow periods and further aligns the CEO’s financial interests with Syntara’s long-term performance and stability. Investors focused on executive alignment may view this favorably.
Shareholder Approval to Be Sought at 2026 Annual General Meeting
The ZEPO grant requires shareholder approval under ASX Listing Rules for related party transactions. Syntara confirmed it will seek approval at its 2026 AGM. The ZEPOs will be issued only after shareholder consent is obtained. The date of the AGM has not yet been announced.
Investors should watch for the formal Notice of Meeting detailing the ZEPO resolution and accompanying explanatory materials, which are expected to provide further context on the CEO’s total remuneration, rationale for the equity-in-lieu-of-cash arrangement, and the Board’s recommendation. Should shareholders reject the proposal, the company would likely pay the $62,359.58 in cash as originally contracted.
Grant Operates Within Syntara’s Employee Incentive Scheme and Option Plan
This ZEPO issuance forms part of Syntara’s broader employee incentive scheme and Employee Option Plan, which govern equity-based compensation for employees and officers. Using an established plan ensures consistent terms and reduces the need for bespoke arrangements requiring separate approvals.
While this update focuses on the CEO, the existence of the scheme suggests wider equity incentive arrangements may be in place. The company did not disclose whether other employees or executives will receive similar ZEPO grants for FY27 or the scheme’s total capacity.
Compliance with ASX Listing Rule 3.10.3 and Appendix 3G Filing
Syntara’s disclosure complies with ASX Listing Rule 3.10.3, mandating notification of proposed related party securities issues, including purpose, class, quantity, and conditions. The company will lodge the required Appendix 3G following shareholder approval. This standard form details new securities and enhances market transparency.
Company Secretary Timothy Luscombe signed the disclosure. The Appendix 3G filing will follow the AGM if approval is granted. Investors tracking Syntara’s share register and Issued Capital should consider the potential addition of up to 3,087,108 ordinary shares post-AGM and upon ZEPO exercise if vesting conditions are met.
What the ZEPO Grant Indicates About Syntara’s Capital Management Strategy
The board’s approval and the CEO’s acceptance of salary in ZEPOs rather than cash signal a deliberate approach to managing cash resources. By converting $62,359.58 of contracted cash pay into equity, Syntara preserves that cash during FY27. For a clinical-stage pharmaceutical company of Syntara’s scale, conserving cash is vital to sustaining operations and funding ongoing programs.
While the company has not explicitly stated cash conservation as the motivation nor commented on its current cash runway in this filing, investors should review Syntara’s latest financial statements and cash flow reports to assess the broader financial context. The immediate impact on Syntara’s share price was not evident from public information.
